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The International Agency for Research on Cancer (IARC) placed the most widely used herbicide 
glyphosate (GLY) into the category 2A (probably carcinogenic to humans), a classification questioned by 
experts from academia and industry. This article critically appraised the epidemiological and experimental 
data that led the IARC working group (WG) to consider GLY a probable human carcinogen and the ensuing 
controversy. An association of GLY with non-Hodgkin lymphoma was suggested by some observational 
studies. A non-causal explanation for this weak association, however, cannot be excluded. Contrary to 
WG’s view, long-term rodent assays yielded no convincing evidence that GLY is carcinogenic. The 
mechanistic evidence remains elusive as well. Bacterial reverse mutation tests (including tester strains 
sensitive to oxidative mutagens) were clearly negative, and so were rodent genotoxicity assays by oral 
route. Tests with mammalian cells in vitro yielded conflicting results at high (cytotoxic) concentrations 
of GLY-based formulations. Conflicting results were also obtained when high doses of GLY-based 
herbicides were administered to rodents by the intraperitoneal route. Such high doses are unlikely to 
be attained in realistic scenarios of exposure. Finally, the IARC classification is based on a conjectural 
hazard, and rational public health interventions must be based on estimated risks.
Keywords: Pesticides/ toxicity. Glyphosate/ adverse effects. Carcinogens. Cancer risk. Hazard/ adverse 
effects. Genotoxicity/prevention and control.
INTRODUCTION
Glyphosate  (GLY) (Figure  1)  i s  a  broad-
spectrum herbicide that acts by inhibiting EPSPS 
(5-enolpyruvylshikimate-3-phosphate synthase) a key 
enzyme that mediates the aromatic amino acid synthesis 
(shikimate) pathway in plants. In Brazil and in other 
soybean producing countries, the use of GLY dramatically 
increased after the introduction of GLY-resistant GM-
soybean crop varieties in the 1990s. Since the general 
population is widely exposed to trace amounts of GLY in 
food products, and a number of pesticide applicators are 
heavily exposed to GLY-based herbicides, any concerns 
about GLY-mediated adverse effects on health need to 
be properly clarified. Along this line, this review article 
addresses the current controversy on whether GLY has (or 
has not) the potential to cause cancer in humans.
THE EMERGENCE OF THE CONTROVERSY 
ON GLYPHOSATE CARCINOGENICITY
In March 2015, the International Agency for 
FIGURE 1 - Glyphosate (GLY) or N-(phosphonomethyl)glycine 
(molecular mass: 169.07) is the most widely used herbicide in 
Brazil and elsewhere. GLY molecule consists of two moieties 
(glycine and methylene phosphonic acid) which don’t carry any 
genotoxic alert and have no oxidative reactivity. After absorption 
in the GI tract, GLY undergoes no subsequent biotransformation 
and is excreted (unchanged) in the urine.
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Research on Cancer (IARC) assessed glyphosate (GLY) 
as probably carcinogenic to humans (Group 2A) (Guyton 
et al., 2015; IARC, 2015). Afterwards, in November 
2015, an assessment by the European Food Safety 
Authority (EFSA) concluded that: “...glyphosate is 
unlikely to pose a carcinogenic hazard to humans and the 
evidence does not support classification with regard to 
its carcinogenic potential according to Regulation (EC) 
No. 1272/2008” (EFSA, 2015). The same conclusion 
was reached by the JMPR (Joint FAO/WHO Meeting 
on Pesticide Residues) meeting held in May 2016: 
“… glyphosate is unlikely to pose carcinogenic risks 
to humans from exposure through the diet” (JMPR, 
2016). Likewise, a risk assessment carried out by the 
US EPA arrived at the conclusion that “... glyphosate 
is not likely to be carcinogenic to humans” (EPA, 2017). 
Moreover, the European Chemicals Agency (ECHA), the 
German Federal Institute for Risk Assessment (BfR – 
Bundesinstitut für Risikobewertung), the Canadian Pest 
Management Regulatory Agency (PMRA), the Australian 
Pesticides and Veterinary Medicines Authority (APVMA), 
the Japanese Food Safety Commission, and the EPA New 
Zealand (BfR, 2017) endorsed the conclusion that GLY 
poses no carcinogenic risks to humans. 
It is of note that, as stated in the preamble to the 
monographs, IARC only evaluates data that were made 
publicly available (IARC, 2015), whereas assessments 
by regulatory agencies (e.g., ECHA, JMPR, EFSA 
and USEPA) are based on a more complete dataset 
that includes unpublished data from studies performed 
by the pesticide industry. The incompleteness of the 
evaluated dataset, however, is not the only explanation 
for divergences between the IARC and other agencies 
regarding GLY carcinogenicity.
The disagreement between the IARC and regulatory 
agencies over the carcinogenicity of GLY was promptly 
echoed by many experts in academia and industry, and 
gave rise to reviews, letters and position papers (Boobis et 
al., 2016; 2017; Portier et al., 2016; Loomis et al., 2017; 
Portier, Clausing, 2017; Tarazona et al., 2017a; b). 
The debate sparked by the classification of GLY as a 
probable carcinogen extended beyond the particular case 
of this herbicide and brought into question the IARC’s 
hazard-based classification scheme for carcinogenicity. 
In June 2016 the Lancet Oncology published an editorial 
(“When is a carcinogen not a carcinogen?”) addressing 
the problem of “determining reliable findings when data 
are equivocal and there are vested interests”, and the 
difficulties of “translating carcinogenicity research into 
appropriate health policies and recommendations for risk 
management” (When …, 2016).
In the following lines, we analyze the strength of the 
experimental and epidemiological evidence supporting 
IARC’s view that GLY is “probably carcinogenic to 
humans”. The evidence evaluated by the IARC working 
group (WG) was presented and discussed at length in the 
Monograph 112, while the agency’s classification scheme 
and its rationale was described in the preamble to the 
monograph (IARC, 2015).
GLYPHOSATE CARCINOGENICITY, WHAT 
SAYS THE EVIDENCE?
Evidence in humans
The evidence in humans came from observational 
studies showing an increased risk of non-Hodgkin 
lymphoma and B-cell lymphoma among exposed workers 
(Guyton et al., 2015; IARC, 2015). A meta-analysis 
of investigations on the association of non-Hodgkin 
lymphoma (NHL) with occupational exposure to 
pesticides, authored by IARC epidemiologists (Schinasi, 
Leon, 2014), illustrates the type and strength of the 
evidence in humans that led the WG to place GLY into 
the 2A category (Figure 2). Three case-control studies 
(Hardell, Eriksson, Nordstrom, 2002; De Roos et al., 
2003; Eriksson et al., 2008) found an association of NHL 
with GLY whereas three others found no association 
(McDuffie et al., 2001, De Roos et al., 2005; Orsi et al., 
2009). The meta-analysis risk ratio estimate (and 95% CI) 
of association between GLY and NHL was 1.5 (1.1-2.0), 
yet the variability across studies due to heterogeneity 
was moderately large (I2=32.7%). The meta-analysis risk 
ratio (RR) estimate (95% CI) for (NHL subtype) B-cell 
lymphoma (2 studies) was 2.0 (1.1-3.6) (Schinasi, Leon, 
2014). Notwithstanding the fact that the association 
was weak, and the inconsistency across studies due to 
heterogeneity, the WG arrived at the conclusion that 
there was “limited” evidence in humans that GLY is 
carcinogenic. A further meta-analysis revealed weak and 
marginally significant associations between “any” versus 
“no” use of GLY and NHL (meta-RR= 1.3, 1.0-1.6 for 6 
studies) and multiple myeloma (meta- RR=1.4, 1.0-1.9, 4 
studies) (Chang, Delzell, 2016). Associations were null for 
Hodgkin lymphoma, leukemia, and NHL subtypes except 
B-lymphoma (2 or 3 studies each). 
A large prospective cohort of licensed pesticide 
applicators (54 251 applicators from North Carolina 
and Iowa in the US) revealed no association between 
GLY and any solid tumors or lymphoid malignancies 
overall, including NHL and its subtypes. Nonetheless, 
an apparently increased risk of acute myeloid leukemia 
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among the most heavily exposed GLY applicators requires 
further confirmation (Andreotti et al., 2018).
As informed in the preamble to the monograph, the 
evidence in humans is classified as “sufficient”, “limited”, 
“inadequate”, or “suggesting lack of carcinogenicity”. 
It is “limited” if “.... causal association is considered 
by the Working Group to be credible, but chance, bias 
or confounding could not be ruled out with reasonable 
confidence”, and “inadequate” if “... available studies are 
of insufficient quality, consistency or statistical power to 
permit a conclusion regarding the presence or absence of 
a causal association ...”.
Actually, if bias and confounding cannot be ruled 
out, one cannot exclude with reasonable confidence a 
non-causal explanation for the observed association. 
That association does not imply causation is a “mantra” 
of analytical epidemiology. Austin Bradford Hill, in his 
remarkable comment on the topic, listed the aspects 
that should be considered before excluding non-causal 
explanations for observed associations (Hill, 1965). 
The strength of the association ranked first in Hill’s list 
and Richard Doll made it clear that, when relative risks 
are small, of the order of 2:1 or even less, the problems 
of eliminating bias and confounding are immense and 
may require massive data (Doll, 2002). In contrast with 
experimental investigations, in observational studies 
systematic errors (biases and confounding) are often more 
relevant than the random error. Moreover, in addition to 
being weak, the associations between GLY and some 
lymphohematopoietic cancers lacked consistency and 
specificity; i.e., the association with one particular type of 
cancer has not been consistently detected across studies. 
Whether the evidence is “limited” or “inadequate”, 
therefore, depends ultimately on a subjective judgment 
that may be influenced by WG members’ aprioristic beliefs 
(How “credible” is the notion that observed associations 
are causal?).
Evidence in experimental animals
The WG conclusion that there was sufficient 
evidence in animals that GLY poses a carcinogenic hazard 
stands basically on findings from long-term studies in 
mice (dietary administration, 2 studies) and rats (diet, 2 
studies). Detailed reports by the EPA on study findings 
were the primary source of the data analyzed by the WG 
(IARC, 2015). 
Mouse. In one CD-1 mouse study (24 months, 50 
M and 50 F/group, 24 months, GLY: 0, 1 000, 5 000 or 30 
000 ppm) the increasing levels of the herbicide in the diet 
induced a positive trend in the incidence of renal tubule 
carcinoma in males (0/49, 0/49, 1/50, 2/50). Another study 
in CD-1 mice (104 weeks, 50 M and 50 F/group, GLY: 0, 
100, 300, 1 000 mg/kg body weight/day) found a positive 
trend for hemangiosarcoma in males (0/50, 0/50, 0/50, 
4/50) but not in females (0/50, 2/50, 0/50, 1/50). It is of 
note that, although being conducted with the same CD-1 
mouse strain, the second study failed to reproduce the 
positive trend for renal tubule carcinoma observed in the 
first study and vice versa (i.e., for hemangiosarcoma). In 
other words, the two mouse studies did not confirm each 
other’s findings.
FIGURE 2 - IARC’s cancer hazard-based classifcation scheme. The classification into a cancer-hazard category (Group 1, 2A, 2B, 
3 or 4) relies fundamentally on a separate assessment of the evidence in humans and in animals. The IARC overall cancer-hazard 
category may be adjusted upwards or downwards depending on the strength of the evidence on the underlying mechanisms of 
carcinogenesis and whether or not they are likely to operate in humans.
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Rat. A Sprague-Dawley rat study (24 months, 60 M 
and 60 F/group, 10 rats/group euthanized after 12 months, 
GLY: 0, 2 000, 8 000 or 20 000 ppm) found a non-dose 
related increase in pancreas islet cell adenomas in males 
(M: 1/58, 8/57, 5/60, 7/59; F: 5/60, 1/60, 4/60, 0/60) and 
no increase in islet cell carcinomas (M: 1/58, 0/57, 0/60, 
0/59; F; 0/60, 0/60, 0/60,0/59). A second study in Sprague-
Dawley rats (life time exposure up to 26 months, 50 M 
and 50 F/group, GLY: 0, 30, 100 or 300 ppm, or 0, 3, 10 
or 31 mg/kg body weight/day) yielded a similar result for 
pancreatic islet cell adenomas (M: 0/50, 5/49, 2/50, 2/50; 
F: 2/50, 1/50, 1/50, 0/50) and carcinomas (M: 0/50, 0/49, 
0/50, 1/50; F:0/50, 1/50, 1/50, 1/50). 
Two other long-term (24 months) studies in Sprague-
Dawley (Séralini et al., 2014) and Wistar (Chruścielska 
et al., 2000) rats, in which GLY-based formulations 
were given via drinking water, showed no significant 
increase in tumor incidence in any treated group. Owing 
to methodological deficiencies and incompleteness of 
study reports, the WG considered the evidence from these 
studies inadequate for the evaluation of GLY. 
The occurrence of pancreatic islet cell adenomas 
was consistently noted in male and female rats in both 
studies evaluated by the WG (EPA report), yet it was also 
recorded in untreated animals and, among the treated 
ones, the incidence was unrelated to the dose of GLY. 
Moreover, as commented by Williams et al. (2016a, b), 
pancreatic islet cell adenoma is a relatively common 
tumor in rats (a non-malignant lesion) and, in the two 
studies, there was no indication of progression to islet 
cell carcinoma.
In one of the two rat studies, a significant trend 
of increase in hepatocellular adenomas and thyroid 
C-cell adenomas was observed. Both lesions, however, 
occurred also in untreated animals (they are relatively 
common histopathology findings in rats), and there was 
no indication of progression to carcinomas. 
In summary, we do believe, and so many other 
experts do (Williams et al., 2016a; Tarazona et al., 2017a), 
that the WG over-interpreted the available data when their 
members deemed that long-term rodent studies provided 
“sufficient” evidence of GLY carcinogenicity. 
Evidence on possible underlying mechanisms
Although the classification of an agent into one 
of the 5 categories stands primarily on the cancer data 
in exposed humans (epidemiology studies) and animals 
(long-term carcinogenicity assays), the overall rating 
may be adjusted upwards or downwards depending on 
the strength of the evidence on the potential underlying 
mechanisms and whether or not they are likely to operate 
in humans (Figure 2).
Genetic damage
Based on the evaluation of three cytogenetic 
biomonitoring studies in exposed humans and a very 
large number of studies in mammalian cells in vitro and 
in experimental animals, the WG concluded that there 
was “strong evidence that exposure to GLY or GLY-based 
formulation is genotoxic” (IARC, 2015). This notion is 
at odds with the conclusion reached by a comprehensive 
review of the data on the genotoxic potential of GLY 
that included a set of unpublished regulatory studies 
(Kier, Kirkland, 2013). Moreover, it is at variance with 
the conclusions of a recent analysis of genotoxicity 
data on GLY and GLY-based formulations conducted 
by an expert panel (Brusick et al., 2016; Williams et al., 
2016a). Kier, Kirkland (2013) noted that there was “an 
overwhelming preponderance of negative results in well-
conducted bacterial reversion and in vivo mammalian 
micronucleus and chromosomal aberration assays”, and 
that “negative results for in vitro gene mutation and a 
majority of negative results for chromosomal effect assays 
in mammalian cells” are additional indications that GLY 
is not typically genotoxic for these endpoints. According 
to the authors, reports of positive results for DNA damage 
endpoints in some tests indicated that GLY and GLY-based 
formulations tend to elicit DNA damage effects at high 
(and toxic) levels, and that these effects were probably 
secondary to cytotoxicity rather than a consequence 
of DNA interaction with GLY, and that the effects may 
be caused by surfactants present in many herbicide 
formulations (Kier, Kirkland, 2013). The WG, however, 
decided not to evaluate the data (66 unpublished regulatory 
studies) provided in a supplement to Kier and Kirkland’s 
review because they would not meet the inclusion criteria 
laid down in the preamble to the monograph, i.e., these 
studies were neither “reports that have been published or 
accepted for publication in the openly available scientific 
literature” nor “governmental reports that are publicly 
available” (IARC, 2015).
The strength of the evidence from studies on the 
genotoxicity of GLY and or GLY-based formulations 
that were included in the IARC monograph is critically 
appraised in the next sections.
Studies in exposed humans
The WG evaluated three studies of genetic damage 
in exposed humans. Paz-y-Miño et al. (2007) noted that the 
incidence of DNA strand breaks (Comet assay) in blood 
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cells collected from 24 people living in sprayed areas 2 
weeks to 2 months after the aerial spraying of GLY was 
higher than the incidence determined in 21 individuals 
living in unsprayed areas. A limitation of Paz-y- Miño et 
al. (2007)’s study (and of ecological-type study designs) 
is that a number of possible biases and confoundings 
remained uncontrolled. A further study by the same 
group found no increase in chromosomal abnormalities 
in the blood cells of 92 people living in sprayed areas of 
northern Ecuator (compared to the incidence observed in 
90 unexposed healthy individuals) two years after the last 
aerial spray of GLY (Paz-y-Miño et al., 2011). Bolognesi 
et al. (2009) evaluated the incidence of cytokinesis block 
micronucleus in lymphocytes from 137 women and their 
spouses living in Colombia regions where GLY was 
sprayed. Blood samples were taken prior to spraying 
(baseline incidence), and 5 days and 4 months after GLY 
spraying. The results suggested that there was a small and 
transient increase in the occurrence of micronucleus in 
lymphocytes after GLY exposure. According to Bolognesi 
et al. (2009), the genotoxic risk associated with GLY 
exposure during aerial spraying for coca and poppy 
eradication in Colombia was low.
Bacterial (reverse mutation) assays
Only two Salmonella typhimurium (and E.coli 
WP2) assays were evaluated by the WG. A study by Li, 
Long (1988) found no mutagenic effect (reverse mutation) 
of GLY (tested up to 5000 µg per plate) in a standard 
testing battery including S.typhimurium strains TA1535, 
TA1537, TA1538, TA98 and TA100, and E.coli WP2, 
without and with extrinsic metabolic activation (rat liver 
TABLE I - Weaknesses of the evidence considered by the IARC working group to place glyphosate into category 2A (“probably 
carcinogenic to humans”)
Evidence (in) Data (from) WG’s assessment Weaknesses of the evidence
Humans
Observational 
studies 
(case-control)
Limited
Non-causal associations cannot be ruled out.
- Associations (NHL and B-cell lymphoma) were weak (meta-
analysis RR ≤ 2) and only marginally significant (lower limits 
of 95% CI = 1 or 1.1)
- Lack of consistency and specificity of findings
- A large prospective cohort found no association between 
GLY and any solid tumor and lymphoid malignancies.
Animals
Rodent 
carcinogenicity 
assays
Sufficient
Mice:
- Statistical significance and dose-response was undemonstrated 
or questionable. 
- 02 CD-1 mouse assays did not confirm each other’s tumor 
findings.
Rats:
- Pancreatic islet cell adenomas, hepatocellular adenomas and 
thyroid C-cell adenomas are non-malignant lesions that also 
occurred in untreated rats.
- No indication of adenoma progression to carcinoma.
Mechanistic
In vitro and in 
vivo assays for 
genotoxicity and 
biomarkers of 
oxidative stress.
Strong 
- Bacterial reverse mutation assays (with strains sensitive to 
oxidative mutagens) yielded negative results.
- In vitro assays with mammalian cells gave rise to conflicting 
results. Positivity noted at high and cytotoxic concentrations of 
some formulated products.
- In vivo genotoxicity assays were negative when rodents were 
treated orally.
- In vivo assays produced conflicting results when rodents were 
treated by the ip route with formulated herbicide products.
- Oxidative stress and genotoxic damage noted only at 
concentrations (in vitro) and doses (in vivo) unattainable in any 
realistic scenario of human exposure to GLY-based herbicides 
IARC: International Agency for Research on Cancer; NHL- Non-Hodgkin lymphoma , GLY: glyphosate, WG: IARC expert 
working group
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S9). Another study by Rank et al. (1993) tested a GLY 
herbicide (Round up®) in two S.typhimurium tester strains 
and found a positive result with TA 98 in the absence of 
Aroclor-induced rat liver S9 mix, and a positive response 
with TA100 in the presence of S9 mix. Rank et al. 
(1993)’s results with TA98 and TA100, however, showed 
no dose-dependent responses and were not consistently 
reproduced in two independent tests. Rank et al.’s study, 
therefore, produced inconsistent and inconclusive results. 
Accordingly, in a summary published after the meeting, 
the WG stated that bacterial mutagenesis tests conducted 
with GLY and GLY-based formulations were negative 
(Guyton et al., 2015).
Mammalian cell in vitro assays
An in vitro mutagenicity test (hprt locus mutation) 
in Chinese hamster ovary cells (CHO-K1BH4 cell line), 
with and without metabolic activation, indicated that GLY 
(up to 22 500 µg/mL) was not genotoxic (Li, Long 1988). 
Nonetheless, a set of genotoxicity tests of GLY and GLY-
based herbicides in mammalian cells in vitro produced 
conflicting results. GLY proved not to be genotoxic in 
the test of unscheduled DNA synthesis (Fischer 344 rat 
hepatocytes, 125 µg/mL) (Li, Long 1988). Mañas et al. 
(2009) found that GLY, tested in the absence of metabolic 
activation, increased DNA strand breaks (comet assay) 
in a human hepatoma cell line (Hep-2) at a concentration 
as high as 3 mM or 507.2 µg/mL, yet it failed to enhance 
the incidence of chromosome aberrations (CA) in human 
lymphocytes in vitro, even at a concentration as high as 6 
mM or 1015 µg/mL (tested levels: 0.2–6.0 mM). Mladinic 
et al. (2009), noted an increase in DNA strand breaks 
(standard and hOGG1 comet assay with and without S9), 
while a test for micronuclei formation (MN) gave rise 
to negative results without S9, and equivocal responses 
in the presence of metabolic activation (at 580 µg/mL). 
Summarizing their results, Mladinic et al. (2009) pointed 
out that no clear concentration-dependent response was 
noted in any assay, and suggested that GLY, at human 
relevant concentrations, poses no significant health risk. 
Monroy et al. (2005) observed that GLY enhanced DNA 
strand breaks in human fibroblast GM38 (4 mM or 676 
µg/mL) and fibrosarcoma HT1080 (4.75 mM or 803 µg/
mL) cell lines without metabolic activation. In a human 
fibroblast cell line (GM5757), Lueken et al. (2004) 
investigated whether a set of non-genotoxic chemicals 
(including GLY) would interact synergistically with 
H2O2 in inducing DNA strand breaks, and obtained an 
equivocal response for a very high concentration of GLY 
(75 mM or 12 680 µg/mL; without S9). Bolognesi et al. 
(1997) observed an enhancement of sister chromatid 
exchanges (SCE) in human lymphocytes exposed in vitro 
(without S9) to high concentrations of GLY (1000 µg/
mL) and GLY-based products (100 µg/mL). Under similar 
experimental conditions (human lymphocytes without S9), 
Vigfusson, Vyse (1980) reported that Round up® 250 µg/
mL enhanced SCE. In an in vitro study considered by the 
WG as being of “limited quality”, Gasnier et al. (2009) 
noted that a GLY-based formulation (5 ppm, without S9) 
increased DNA strand breaks in human liver HepG2 cells. 
Koller et al. (2012) found that both GLY and Round up® 
increased DNA strand breaks in a buccal epithelial cell line 
(TR146) treated with concentrations ≥ 20 µg/mL in the 
absence of S9. Alvarez-Moya et al. (2014) reported that 
GLY increased DNA strand breaks in human lymphocytes 
in vitro (without S9), yet the magnitude of the increase in 
tail length remained practically unchanged over a large 
interval of tested concentrations (from 0.7 to 0.0007 mM). 
Roustan et al. (2014) evaluated in a Chinese hamster ovary 
cell line (CHO-K1) whether pesticides and their mixtures 
caused photo-inducible cytogenetic toxicity (MN) with 
and without metabolic activation. GLY had no effect in 
the absence of S9, but it was clastogenic (10 µg/mL) when 
tested with metabolic activation in the dark. In another 
study, Lioi et al. (1998) treated bovine lymphocytes 
cultured in vitro (without S9) with GLY (17 µM or 3 µg/
mL) and observed that it increased SCEs and CAs. Still 
in cultured bovine lymphocytes, Siviková, Dianovský 
(2006) noted that a GLY-based formulation (56 µM) 
increased SCEs in the absence (but not in the presence) of 
S9, although it induced no CA (without S9) even at levels 
as high as 1120 µM (190 µg/mL).
In  summary,  t he  Sa lmone l l a /mic rosome 
mutagenicity assay was frankly negative while tests in 
mammalian cells in vitro yielded conflicting results. Most 
positive (clastogenic effects) findings, however, were 
observed at high (cytotoxic) concentrations of GLY-based 
formulations.
Mammalian in vivo assays
Although humans are exposed to GLY by the oral 
and dermal routes, and occasionally by inhalation, except 
for two mouse studies, the rodent genotoxicity assays 
evaluated by the WG used the intraperitoneal (ip) route 
(IARC, 2015). A dominant lethal study (EPA report) found 
no evidence of genotoxic effects of GLY administered 
by gavage (2000 mg/kg body weight) to CD-1 mice. 
Another study revealed no increase in two endpoints for 
clastogenicity (CA and MN in polychromatic erythrocytes 
- PCEs) in male C57BL mice treated orally with a GLY-
based formulation (1080 mg/kg body weight) (Dimitrov 
et al., 2006).
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Seven studies investigated the genotoxicity of GLY 
and GLY-based formulations administered by ip injections. 
Bolognesi et al. (1997) reported positive genotoxic 
responses in male CD1 mice treated with GLY (300 mg/kg 
body weight ip) or Round up® (~300 mg/kg body weight 
ip) in a variety of endpoints and tests (DNA adducts and 
or strand breaks in the liver and kidneys and MN in bone 
marrow cells). Mañas et al. (2009) described that male and 
female BalbC mice treated with GLY (400 mg/kg body 
weight ip) showed a higher frequency of MN-PCEs in 
the bone marrow. Prasad et al. (2009) found an increased 
incidence of CA and MN-PCEs in the bone marrow of 
male Swiss mice treated with Round up® (25 and 50 mg/
kg body weight ip), a treatment that was myelotoxic 
as indicated by a decrease in the mitotic index of bone 
marrow cells. In this study clastogenic and myelotoxic 
effects were noted at doses much lower than the lowest 
effective doses (LED) determined in the other positive 
studies (one tenth the LED or even less), and dimethyl-
sulfoxide (DMSO) was used as a vehicle to Round up®. 
The use of DMSO is amazing because Round up® is a 
water-soluble GLY-based formulation.
Peluso et al. (1998) treated male and female CD-1 
mice with GLY (270 mg/kg body weight ip) or Round up® 
(600 mg/kg body weight ip) and found negative responses 
(DNA adducts, liver and kidneys) for GLY and positive 
effects for the formulated product. These results led the 
authors to conclude that the observed DNA damage was 
caused by a component of the herbicide mixture other than 
the active ingredient (GLY). 
Three other rodent studies on the genotoxic potential 
of GLY or GLY-based formulations given by the ip route 
reported negative results. Rank et al. (1993) found no 
clastogenic effect (MN assay) of GLY and Round up® (up 
to 200 mg/kg body weight ip) in male and female NMRI 
mice. Grisolia (2002) gave Round up® to male and female 
Swiss Webster mice by the ip route (up to 200 mg/kg body 
weight) and noted no increase in the incidence of MN-
PCEs in the bone marrow. Li, Long (1988) treated male 
and female Sprague-Dawley rats with GLY (1000 mg/kg 
body weight, ip) and found no increase in the occurrence 
of CAs in bone marrow cells. 
I n  summary,  two  s tud i e s  i nvo lv ing  o r a l 
administration of GLY or GLY-based formulations to 
mice found no evidence of genotoxicity. Nonetheless, 
studies in which rats or mice received ip injections of 
GLY or GLY-based formulations gave rise to conflicting 
results. A confounding variable when GLY and GLY-based 
formulations - at high concentrations – are injected directly 
into the peritoneal cavity of rodents is the potential local 
toxicity (irritancy) of these preparations. Ingredients with 
skin and mucosal irritant properties such as surfactants 
(e.g., polyethoxylated tallow amine, POEA) and sulfuric 
and phosphoric acids are often added to GLY formulations 
and their types and concentrations may differ among 
formulations (IARC, 2015).
Oxidative stress
The WG concluded that studies in animals and 
human cells in vitro provided “strong evidence” that GLY 
and GLY-based formulations can enhance intracellular 
levels of reactive oxygen species (ROS). Since ROS 
(e.g., superoxide anion, O2−, hydrogen peroxide, H2O2, 
and hydroxyl radicals, OH-) can damage macromolecules 
(lipids, proteins and DNA), the oxidative stress (OS) 
may enhance mutation rates and, by doing so, cancer 
initiation. ROS levels and biological effects, however, 
seem to exhibit biphasic (hormetic) dose-responses, 
i.e., low levels of ROS activate signaling pathways to 
initiate physiological processes and adaptive responses 
and higher levels (OS) may damage cell lipids, proteins 
and DNA. 
Some in vitro studies with human cells examined the 
effects of GLY and GLY and GLY-based formulations on 
OS parameters. A MTT assay with human keratinocyte cells 
(HaCaT) showed that GLY and GLY-based formulations 
are cytotoxic when applied in the mM concentration range 
(IC50s 17-23 mM), and that addition of ascorbic acid to the 
culture medium increased the IC50s (Gehin et al., 2005). 
Using the HaCaT cell line, Elie-Caille et al. (2010) noted 
that GLY, at concentrations as high as 21 mM, increased 
the production of H2O2 (dichlorodihydrofluorecein 
diacetate assay, DCDA). George, Shukla (2013) reported 
that addition of a GLY formulation (0.1 mM) to HaCaT cell 
culture medium enhanced ROS generation (DCDA), an 
effect that was partially antagonized by N-acetyl-cysteine. 
Chaufan, Coalova, Molina (2014) described that a GLY 
formulation (40 mg/L), but not GLY 95% pure (900 mg/L), 
enhanced ROS formation by the human liver HepG2 cell 
in culture. A subsequent study with human HEp-2 cells 
found that a GLY-based herbicide (Atanor®), applied at 
levels as high as 376.4 mg/L, induced ROS formation 
(DCDA), catalase activity and glutathione levels, and did 
not change superoxide dismutase (SOD) and gluthatione-
S-transferase (GST) activities (Coalova, Molina, Chaufan, 
2014). Mladinic et al. (2009) treated human lymphocytes 
in vitro and noted that, with and without addition of S9, 
GLY (98% pure, 580 µg/mL) increased lipid peroxidation. 
Kwiatkowska, Huras, Bukowska (2014) reported 
that, in human lymphocytes exposed in vitro, GLY, at 
concentrations as high as 0.25, 0.5 and 5.0 mM, caused a 
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small (<20%) yet statistically significant enhancement of 
ROS formation (DCDA).
Various studies investigated whether GLY and or 
GLY-based formulations induce OS in rodents. Astiz, 
Alaniz, Marra (2009) injected GLY (10 mg/kg body weight 
ip), zineb or dimethoate and mixtures of these pesticides 
into male Wistar rats and noted changes in OS biomarkers 
in the blood plasma, kidney and liver, particularly among 
the animals treated with mixtures. Cattani et al. (2014) 
exposed rats to Round up® (1% in the drinking water) 
during pregancy and lactation up to postnatal day 15 and 
noted changes in brain (hippocampus) slices of the exposed 
pups (15-day old) and concluded that this herbicide 
formulation could lead to glutamate excitocitoxicity 
and OS. Two other studies evaluated OS biomarkers in 
mice treated ip with GLY or GLY-based formulations. 
Bolognesi et al. (1997) reported that GLY and GLY-based 
formulation (300 mg/kg body weight ip) induced oxidative 
DNA damage in the liver and or kidneys of CD1 mice. 
Cavuşoğlu et al. (2011) described that, in Swiss mice, 
Round up® (50 mg/kg body weight ip) increased serum 
biomarkers of liver and kidney injury (AST, ALT, BUN 
and creatinine), and decreased GSH levels and enhanced 
malondialdehyde (MDA) concentrations in the liver and 
kidneys. Jasper et al. (2012) evaluated the toxicity of 
Round up® given orally to Swiss mice (50 and 500 mg/
kg body weight/day) for 15 days. The authors noted a rise 
in ALT, AST and γ-GT in the blood serum, and enhanced 
lipid peroxidation (TBARS) and reduced GSH levels in 
the liver of males (both doses) and females (highest dose). 
In a tumor promoting assay in Swiss mice, George et al. 
(2010) noted that a GLY formulation applied on the skin 
(25 mg/kg body weight, 3 times per week for 32 weeks) 
induced changes in the treated area consistent with OS.
In summary, studies with human cell lines suggested 
that GLY and GLY-based formulations, if added to the 
culture medium at concentrations in the mM range, may 
elicit OS and oxidative DNA lesions. Such levels of GLY 
in the extracelular medium, however, are unlikely to 
be attained when humans are exposed through the diet, 
and or during the preparation and application of GLY-
based herbicides. Non-human mammalian studies, on 
the other hand, were conducted mostly by non-relevant 
routes of administration (ip) and tested unrealistic high 
doses. US EPA conservative estimate for exposures of 
the general population via food and water was 0.088 mg 
of GLY/kg body weight/day (range 0.058-0.23), while for 
applicators, 90th centiles for systemic exposures based on 
biomonitoring and dosimetry normalized for penetration 
through the skin were 0.0014 and 0.021 mg/kg body 
weight/day, respectively (Solomon, 2016). Moreover, 
some studies of GLY-based formulations in rodents are 
confounded by the substantial liver and kidney toxicity, 
and toxic (irritant) formulation ingredients other than GLY.
The overall evidence
The limited evidence in humans supporting WG’s 
classification of GLY into 2A category was a positive 
association (marginally significant, lower limit of 95% 
CI= 1 or 1.1) between workers’ exposure to GLY-based 
herbicides and NHL and or B-cell lymphoma detected by 
a meta-analysis of case-control studies. This association, 
however, was weak and thus a non-causal explanation 
for it cannot be ruled out. A further large cohort study 
(Andreotti et al., 2018) found no association between 
NHL and occupational exposure to GLY-based herbicides.
The evidence in animals, on the other hand, 
refers to a “positive trend” in the incidence of renal 
tubule carcinoma among males in one mouse study and 
hemangiosarcoma in male mice from another study. The 
two CD-1 mouse studies, however, did not reproduce each 
other’s findings. Moreover, the statistical significance 
and dose-response relationships were not convincingly 
demonstrated (Williams et al., 2016a; b). A non-dose 
related increase in pancreatic islet cell adenomas was 
found in two rat studies. Nonetheless, these are non-
malignant lesions also found in untreated animals and 
no indication of progression to islet cell carcinoma was 
noted in both rat studies. The WG conclusion that these 
data provided “sufficient” evidence of carcinogenicity 
in animals therefore seems to be an over-interpretation 
of inconsistent data on the tumor occurrence in life-span 
exposure rodent studies. 
The WG interpretation that the overall data indicated 
that GLY and GLY-based formulations induce “DNA 
and chromosomal damage in mammals” – possibly 
mediated by oxidative stress - was unsupported by a 
critical appraisal of studies’ design details and findings. 
GLY is not an electrophilic compound (Figure 1) and 
results from bacterial assays, including strains sensitive to 
detect oxidant mutagens, were negative. The Salmonella/
microsome assay (Ames’ test) is one of the most sensitive 
mutagenicity tests. It has yielded very few false negative 
results that are generally reversed when a more adequate 
metabolic activation system is used. Carcinogenic 
nitrosamines that are non-mutagenic in the standard Ames 
test, for instance, give a positive response when the rat 
liver S9 is replaced with a hamster liver S9 (Lijinsky, 
Andrews, 1983). There is no reason to think that GLY 
could be activated by an extrinsic metabolic activation 
system other than the rat liver S9. That is, the negative 
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results of assays with a comprehensive set of bacterial 
tester strains, including those strains sensitive to oxidative 
mutagens, is a strong evidence that GLY is not mutagenic. 
Overall, results from in vitro assays with mammalian 
cells suggested that GLY at non-toxic concentrations did 
not induce DNA and or chromosomal damage. Along 
this line, GLY proved not to be genotoxic when mice 
were treated orally. Conflicting results, however, were 
obtained when rodents received ip injections of GLY-based 
herbicides. In rodents treated by the ip route, changes 
in genotoxic endpoints were generally noted only at 
high doses and may have been secondary to a systemic 
toxicity. The contribution of ingredients of GLY-based 
formulations other than GLY to the clastogenic response 
cannot be ruled out either.
CONCLUDING REMARKS
The inclusion of GLY into IARC’s 2A category 
was based on equivocal data provided by a set of 
investigations which are predominantly non-GLP 
studies. As far as public health is concerned, however, 
the heated dispute on whether GLY might eventually pose 
a cancer hazard is much ado about nothing. Actually, 
from a pragmatic standpoint, cost-effective public health 
interventions have to be based on the estimated risks 
(probability to cause harm) and not on a conjecture about 
the potential to cause harm. To estimate carcinogenic 
risks to humans, additional terms such as exposure and 
dose-response relationship must be brought into the 
equation. Along this line, most of the findings that led 
the WG to infer that GLY (probably) poses a cancer 
hazard were noted only at concentrations (in vitro assays) 
or doses (in vivo studies) unattainable in any realistic 
scenario of human exposure. A biomonitoring study 
detected urinary levels of GLY (24-h samples) in 60% 
of the exposed farmers, 4% of their spouses and 12% 
of their children on the day of application. The authors 
found that the mean concentration of GLY in the urine 
was 3 ppb with a maximum level of 233 ppb, and that 
farmers who did not wear gloves had GLY levels much 
higher than those who used this item of individual 
protective equipment (10 versus 2 ppb) (Acquavella et 
al., 2004; Araujo, Delgado, Paumgartten, 2016). Data 
from biomonitoring studies, therefore, revealed that, 
even for the most heavily exposed people, exposures to 
GLY were less than the reference dose and the acceptable 
daily intakes (Acquavella et al., 2004; Solomon, 2016). 
A warning in the preamble (monograph 112) 
stresses that classification refers to a speculative cancer 
hazard (e.g., “possible” or “probable” carcinogenicity 
to humans). Notwithstanding reiterating the caveat, 
IARC has maintained the term “risk” in the title of the 
monograph series (“IARC Monographs on the Evaluation 
of Carcinogenic Risks to Humans”) leaving a room for 
misinterpretation. 
Although a monograph elaborated by a group 
of experts adds to the literature available for decision 
makers, the purpose and usefulness of cancer hazard-based 
classification categories remain unclear. In a response to 
a criticism about the IARC classification scheme (Boobis 
et al., 2016), experts from the agency staff (Loomis et al., 
2017) argued that hazard identification provides “..a vital 
platform for the subsequent steps of risk assessment and 
management”. There is no doubt that hazard identification 
is the initial step of risk assessment and management. 
Summarizing and translating all the available data into 
a cancer hazard category, however, is worthless for a 
subsequent risk assessment. Furthermore, a cancer hazard-
based classification may mislead risk communication and 
decision-making by national regulatory authorities who 
have no technical skills and capabilities to conduct an 
independent risk assessment.
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